Overview

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

This is a single site, prospective pilot study to determine the feasibility and safety of the administration of HP 13C bicarbonate in 10 patients with prostate cancer to determine potential hydrogen (pH) values in surrounding tissue. The proposed study will evaluate pre-surgical participants with histologically confirmed localized prostate cancer who receive infusion of hyperpolarized 13C injection prior to MR imaging with endorectal coil.

Phase:

Early Phase 1

Details

Lead Sponsor:

Robert Flavell, MD, PhD

Collaborator:

U.S. Army Medical Research Acquisition Activity